»
Annual Reports in Medicinal Chemistry
 
 

Annual Reports in Medicinal Chemistry, 1st Edition

 
Annual Reports in Medicinal Chemistry, 1st Edition,Annette Doherty,ISBN9780120405374
 
 
 

Annual Reports in Medicinal Chemistry

A Doherty   

Academic Press

9780120405374

364

189 X 246

Print Book

Hardcover

In Stock

Estimated Delivery Time
USD 180.00
 
 

Description

Annual Reports in Medicinal Chemistry provides timely and critical reviews of important topics in medicinal chemistry together with an emphasis on emerging topics in the biological sciences, which are expected to provide the basis for entirely new future therapies.

Readership

Medicinal, pharmaceutical, and organic chemists.

Annette Doherty

Affiliations and Expertise

Pfizer Global R&D, Sandwich Laboratories, United Kingdom

View additional works by Annette M. Doherty

Annual Reports in Medicinal Chemistry, 1st Edition

I. CENTRAL NERVOUS SYSTEM DISEASES

Section Editor: David W. Robertson, Pfizer Global Research & Development, Ann Arbor, MI


1. Promise and Progress of Central G-Protein Coupled Receptor Modulators 1
for Obesity Treatments
Brian L. Largent, Albert J. Robichaud and Keith J. Miller, Bristol-Myers
Squibb Company, Wilmington, Delaware


2. Attention Deficit Hyperactivity Disorder: Pathophysiology and Design of 11
New Treatments
Shelly A. Glase, Larry D. Wise and David W. Robertson, Pfizer Global Research and Development, Ann Arbor, Michigan


3. 5-HT2C Receptor Modulators: Progress in Development of 21
New CNS Medicines
Larry E. Fitzgerald and Michael D. Ennis, Pharmacia Corporation, Kalamazoo, Michigan


4. Emerging Themes in Alzheimer's Disease Research: Paradigm Shift in
Drug Discovery 31
Todd Morgan, School of Gerontology, University of Southern California,
Los Angeles, California and Grant A. Krafft, Acumen Pharmaceuticals, Glenview, Illinois

II. CARDIOVASCULAR AND PULMONARY DISEASES

Section Editor: William J. Greenlee, Schering-Plough Research Institute,
Kenilworth, New Jersey


5. Recent Advances in Pulmonary Hypertension Therapy 41
Russell A. Bialecki, AstraZeneca Pharmaceuticals, Wilmington, Delaware


6. Phosphodiesterase 5 Inhibitors 53
Andrew W. Stamford, Schering-Plough Research Institute, Kenilworth,
New Jersey


7. Antagonists of VLA-4 65
George W. Holland, Ronald J. Biediger, and Peter Vanderslice,
Texas Biotechnology Corporation, Houston, Texas


8. Purine and Pyrimidine Nucleotide (P2) Receptors 75
Kenneth A. Jacobson, Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland


9. Anticoagulants: Inhibitors of the Factor VIIa/
Tissue Factor Pathway 85
Leslie A. Robinson and Eddine M. K. Saiah, Deltagen Research Laboratories, San Diego, California




III. CANCER AND INFECTIOUS DISEASES

Section Editor: Jacob J. Plattner, Chiron Corporation, Emeryville, California


10. The Prospect for Microbial Genomics Providing Novel, Exploitable, 95
Antibacterial Targets
Thomas J. Dougherty, Pfizer Global Research & Development, Groton,
Connecticut and John F. Barrett, Merck Research Laboratories,
Rahway, New Jersey

11. The Chemistry and Biology of Tetracyclines 105
Mark L. Nelson, Paratek Pharmaceuticals, Inc., Boston, Massachusetts


12. Intracellular Signaling Targets for Cancer Chemosensitization 115
Thomas G. Gesner and Stephen D. Harrison, Chiron Corporation,
Emeryville, California


13. Emerging Microtubule Stabilizing Agents for Cancer Chemotherapy 125
David C. Myles, Kosan Biosciences, Inc., Hayward, California


14. Antiviral Agents 133
Nicholas A. Meanwell, John F. Kadow and Paul M. Scola,
The Bristol-Myers Squibb Pharmaceutical Research Institute
Wallingford, Connecticut


15. Aerosol Delivery of Antibiotics 149
Peter B. Challoner, Chiron Corporation, Emeryville, California




IV. IMMUNOLOGY, ENDOCRINOLOGY AND METABOLIC DISEASES

Section Editor: William K. Hagmann, Merck Research Laboratories,
Rahway, New Jersey


16. Therapeutic Applications of Non-peptidic d-Opioid Agonists 159
Graham N. Maw and Donald S. Middleton, Pfizer Global Research and Development, Department of Discovery Chemistry, Sandwich, Kent


17. Selective Glucocorticoid Receptor Modulators 167
Michael J. Coghlan*, Steven W. Elmore†, Philip R. Kym†
and Michael E. Kort†, *Eli Lilly and Company, Discovery Chemistry Research & Technologies, DC , †Lilly Corporate Center, Indianapolis, Indiana, Abbott Laboratories, Global Pharmaceutical Research and Development, Illinois


18. Inhibitors of p38 a MAP Kinase 177
Sarvajit Chakravarty and Sundeep Dugar, Scios Inc. Sunnyvale, California

V. TOPICS IN BIOLOGY

Section Editor: Janet M. Allen, Inpharmatica, London, United Kingdom


19. Expanding and Exploring Cellular Pathways for Novel Drug Targets 187
Malcolm P. Weir, John P. Overington and Marlon Schwarz, Inpharmatica Ltd., London,


20. Searching for Alzheimer's Disease Therapies In Your Medicine Cabinet: 197
The Epidemiological and Mechanistic Case For NSAIDs and Statins
Robert B. Nelson, Pfizer Global Research and Development, Groton,
Connecticut


21. Matrix Metalloproteinases and the Potential Therapeutic Role for Matrix 209
Metalloproteinase Inhibitors in Chronic Obstructive Pulmonary Disease
Kevin M. Bottomley and Maria G. Belvisi, Inpharmatica,
London and Respiratory Pharmacology, Cardiothoracic Surgery,
Imperial College School of Medicine, National Heart and Lung Institute, London


22. Fc Receptor Structure and the Design of Anti-inflammatories: New 217
Therapeutics For Autoimmune Disease.
Geoffrey A. Pietersz, Maree S. Powell, Paul A. Ramsland and
P. Mark Hogarth, Austin Research Institute, Austin and
Repatriation Medical Center, Victoria, Australia


23. Tumor classification for tailored cancer therapy 225
Fiona McLaughlin and Nick LaThangue, Prolifix Ltd, Abingdon, Oxon




VI. TOPICS IN DRUG DESIGN AND DISCOVERY

Section Editor: George L. Trainor, DuPont Pharmaceuticals Company,
Wilmington, Delaware


24. Advances in the Discovery and Characterization of Ion Channel 237
Modulators: Focus on Potassium Channels
Valentin K. Gribkoff and John E. Starrett, Jr., Bristol-Myers Squibb
Pharmaceutical Research Institute, Wallingford, Connecticut
25. Microwave-Assisted Chemistry as a Tool for Drug Discovery 247
Carolyn D. Dzierba and Andrew P. Combs, Bristol-Myers Squibb Co. Experimental Station, Wilmington, Delaware




VII. TRENDS AND PERSPECTIVES

Section Editor: Annette M. Doherty, Pfizer Global Research & Development,
Fresnes Laboratories, Fresnes, France


26. To Market, To Market - 2001 257
Patrick Bernardelli, Bernard Gaudillière and Fabrice Vergne, Pfizer Global Research & Development, Fresnes Laboratories, Fresnes, France


27. Biosimulation: Dynamic Modeling of Biological Systems 279
Kevin Hall, Rebecca Baillie, and Seth Michelson, Entelos Inc.,
Menlo Park, California



COMPOUND NAME, CODE NUMBER AND SUBJECT INDEX, VOLUME 37 289

CUMULATIVE CHAPTER TITLES KEYWORD INDEX, VOLUMES 1-37 297

CUMULATIVE NCE INTRODUCTION INDEX, 1983-2001 315

CUMULATIVE NCE INTRODUCTION INDEX, 1983-2001, BY INDICATION 331

Quotes and reviews

"This series is one of the very few annual publications which justify the title of an absolute must for the pharmacologist, chemist, or physician who is interested in the chemistry of drug development."
—ENZYMOLOGIA

"This book is strongly recommended for researchers, teachers, students, administrators—in short, anyone whose interests impinge on medicinal chemistry. In view of the work's documented reference value, it is a must for inclusion in the scientist's personal library."
—JOURNAL OF MEDICINAL CHEMISTRY

"All topics are covered in sufficient depth, with extensive references, to allow either the specialist or the novice to be informed of the latest developments in a particular area of medicinal chemistry."
—JOURNAL OF PHARMACEUTICAL SCIENCES
 
 

Elsevier|Free Shipping

Shop with Confidence

Free Shipping around the world
▪ Broad range of products
▪ 30 days return policy
FAQ

Contact Us